T-bet CAR T cells: A new avenue for NSCLC therapy analyzed in lung cancer-derived organoids 2258880
Chimeric antigen receptor (CAR) T cell therapy in solid tumors is limited by the immunosuppressive tumor microenvironment (TME). Since we have identified T-bet as a strong anti-tumor candidate, we thought to explore new therapies against NSCLC by developing next-generation CAR T cells and patient-derived lung can...